Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH, a common and progressive chronic liver ...

2024 and the Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2024 and the Half-Year Report for the six ...

January 24, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused ...

In a report released on January 27, Sebastien Sztabowicz from Kepler Capital maintained a Sell rating on Telefonaktiebolaget LM Ericsson Class B (0O87 – Research Report), with a price target of ...

Max Kepler hit eight homers last season, the fewest he’s ever hit in a big-league season, which makes him an unlikely source to supply the Phillies’ outfield with more power in 2025.

Kepler Capital Markets upgraded shares of Logitech International (NASDAQ:LOGI – Free Report) from a hold rating to a buy rating in a report issued on Thursday morning, Marketbeat.com reports.

PHILADELPHIA -- Max Kepler had surgery in Philadelphia on Oct. 2 to repair a partially detached abdominal muscle that had bothered him since the summer. He recovered in a hospital room, which featured ...

From the window of the Philadelphia hotel room where Max Kepler was recovering from bilateral core surgery last October, he could see Citizens Bank Park. The Phillies happened to be hosting the Mets ...

Telefonaktiebolaget Lm Ericsson (publ) (NASDAQ: ERIC) Q4 2024 Earnings Call Jan 24, 2025, 3:00 a.m. ET ...

This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 20-F for the fiscal year ended December 31, 2023.